1. Home
  2. EXAS vs GFS Comparison

EXAS vs GFS Comparison

Compare EXAS & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.91

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Logo GlobalFoundries Inc.

GFS

GlobalFoundries Inc.

HOLD

Current Price

$36.33

Market Cap

18.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXAS
GFS
Founded
1995
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
19.3B
18.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EXAS
GFS
Price
$101.91
$36.33
Analyst Decision
Buy
Buy
Analyst Count
20
10
Target Price
$77.94
$40.80
AVG Volume (30 Days)
4.9M
5.5M
Earning Date
02-18-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,082,033,000.00
$6,791,000,000.00
Revenue This Year
$19.40
$1.14
Revenue Next Year
$13.51
$6.15
P/E Ratio
N/A
N/A
Revenue Growth
14.47
0.25
52 Week Low
$38.81
$29.77
52 Week High
$102.66
$47.69

Technical Indicators

Market Signals
Indicator
EXAS
GFS
Relative Strength Index (RSI) 85.29 49.17
Support Level $101.45 $35.32
Resistance Level $102.00 $35.98
Average True Range (ATR) 0.39 1.00
MACD -1.26 -0.31
Stochastic Oscillator 88.69 19.05

Price Performance

Historical Comparison
EXAS
GFS

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About GFS GlobalFoundries Inc.

GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.

Share on Social Networks: